Supernus (SUPN) Form 144: 1,412 Shares Proposed Sale $61,168

Supernus Pharmaceuticals (SUPN) filed a Form 144 reporting a proposed sale of 1,412 shares of its common stock.

Rhea-AI Filing Summary

Supernus Pharmaceuticals (SUPN) filed a Form 144 reporting a proposed sale of 1,412 shares of its common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $61,167.84 and the company reports 56,073,088 shares outstanding. The filing lists the acquisition of these shares as an in-kind distribution from NEA Partners on 11/16/2023, with the acquisition and payment dated 11/16/2023.

The filer indicates no securities sold in the past three months and includes standard representations about absence of undisclosed material adverse information. The notice appears to be a routine disclosure of an intended sale under Rule 144.

Positive

• Complete Rule 144 disclosure including broker, acquisition details, aggregate market value and outstanding shares
• Brokered sale through a regulated firm (Morgan Stanley Smith Barney LLC) listed
• Filer attests to absence of undisclosed material adverse information and reports no sales in past three months

Negative

• None.

Insights

Securities Analyst

TL;DR: Small insider sale disclosed: 1,412 shares worth $61,167.84, routine compliance filing under Rule 144.

The Form 144 provides required details for a proposed sale of 1,412 common shares via Morgan Stanley Smith Barney on NASDAQ. The shares were acquired in-kind from NEA Partners on 11/16/2023. With 56,073,088 shares outstanding reported, the transaction size is limited in absolute terms and the filing contains the customary representation that no undisclosed material adverse information is known.

Compliance/Risk Analyst

TL;DR: Filing meets Rule 144 disclosure elements; no past three-month sales reported.

The notice includes broker details, acquisition date and nature, aggregate market value, and outstanding share count, aligning with Rule 144 form requirements. It also contains the signature representation regarding material information and a statement about reliance on any 10b5-1 plan if applicable. No recent sales are reported, suggesting this is a standalone planned disposition.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Supernus (SUPN) report in this Form 144?

The filing reports a proposed sale of 1,412 common shares through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $61,167.84.

When were the shares being sold acquired?

The shares were acquired on 11/16/2023 as an in-kind distribution from NEA Partners, with payment dated 11/16/2023.

How many Supernus shares are outstanding according to the filing?

The filing lists 56,073,088 shares outstanding.

Does the filing report any securities sold in the past three months?

No. The Form 144 states "Nothing to Report" for securities sold during the past three months.

Who is the broker handling the proposed sale?

The proposed sale is to be handled by Morgan Stanley Smith Barney LLC, Executive Financial Services located at 1 New York Plaza, 8th Floor, New York, NY 10004.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/22/2025 - 05:04 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001005544
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	SUPERNUS PHARMACEUTICALS, INC.
SEC File Number	001-35518
Address of Issuer	9715 Key West Avenue Rockville MARYLAND 20850
Phone	3018382500
Name of Person for Whose Account the Securities are To Be Sold	CHARLES NEWHALL
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1412	61167.84	56073088	08/22/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/16/2023	In-Kind Distribution	NEA Partners			1412	11/16/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon an in-kind distribution during the period of 5/1/2012 through 11/16/2023
Date of Notice	08/22/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/03/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Charles Newhall
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)